Quantcast
Last updated on April 16, 2014 at 21:24 EDT

Glide Pharma Announces Design Optimisation Agreement With Nypro Healthcare For Scale Up Of Solid Dose Delivery Device

July 2, 2013

OXFORD, England, July 2, 2013 /PRNewswire/ –

Glide Pharma today announced that it has entered an agreement with global device
manufacturer Nypro Healthcare to complete the design optimisation of its solid dose
injector in preparation for production scale up. The company’s delivery system, the Glide
SDI(R), is a unique technology for injecting drugs and vaccines in a solid dosage form
without the need for a needle. The Glide SDI(R) comprises a novel tiny solid dosage, which
is pushed into the skin with a small, hand-held, spring-powered device. Nypro Healthcare
will work with Glide Pharma to ensure the design of the device and its components are
optimised for manufacturing scale up and to ensure patient requirements, including
self-administration, are met.

“This agreement marks a milestone for our Glide SDI(R) device as it will enable us to
complete the final phase of development prior to production scale up. As a recognized
leader in the development and manufacturing of precision devices we believe that Nypro
Healthcare is the perfect partner to work with Glide Pharma on advancing our novel
delivery system,” stated Dr Mark Carnegie-Brown, CEO, Glide Pharma.

“The Glide SDI(R) is a highly innovative delivery system, which is very different from
other technologies currently on the market. Nypro Healthcare is delighted to have been
selected as Glide Pharma’s partner to help progress the development of this exciting new
technology,” commented Chris Nother, VP Business Development, Nypro Healthcare.

About the Glide SDI(R) (Solid Dose Injector)

The Glide SDI(R) is an innovative needle-free delivery system. The reusable injector
uses a spring mechanism to administer a tiny solid dosage below the patient’s skin, where
it dissolves and releases the pharmaceutical. Glide’s solid dose formulations eliminate
the risk of needle-stick injuries and avoid time-consuming reconstitution. They also have
the potential to modify the release of medicines and to improve stability, removing the
need for refrigeration. The one-click action, pen-sized device is extremely easy to use,
with medicines supplied in pre-filled disposable cassettes, making it ideal for
self-administration. In clinical testing, volunteers strongly preferred the Glide SDI(R)
to traditional needle and syringe.

About Glide Pharma

Glide Pharma is a pharmaceutical development and device company focused on the easy,
safe and convenient administration of solid dose formulations of therapeutics and
vaccines. The company has a range of in-house and partnered programmes based on its
proprietary solid dose injector, the Glide SDI(R). Glide Pharma has a strong management
team with extensive experience of the pharmaceutical, biotechnology and medical device
sectors. The company has successfully completed five investment rounds, and is supported
by a consortium of institutional and private technology investors, including Invesco
Perpetual, Oxford Technology Venture Capital Trusts, Oxford Capital Partners and Hygea
VCT. For more information please visit http://www.glidepharma.com.

About Nypro Healthcare

Nypro Healthcare is a provider of device development and global manufacturing services
to the world’s leading and emerging pharmaceutical, diagnostics and medical device
companies, supporting from concept, through clinical trials and into commercial
production. Nypro Healthcare is an operating unit of Nypro Inc., a global plastics and
contract manufacturer with $1.2 billion annual revenues, which recently agreed to merge
with Jabil Circuit Inc., a $17 billion electronics products solutions company. For more
information please visit http://www.nypro.com.

        Contacts
        Dr Mark Carnegie-Brown
        Chief Executive
        Glide Pharma
        Tel: +44(0)8700-853700

        Rob Budge
        RJB Communications
        Tel: +44(0)1865-760969
        Mobile: +44(0)7710-741241

SOURCE Glide Pharma


Source: PR Newswire